GlassScriptPhysician profile
Andrew W Carter
NPI 1467415687
$1,042.19
in general payments reported to CMS, 2019-2025
14 companies · $401 in 2025
The $401 reported for 2025 was more than what 75% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $300 · 2021: $17.95 · 2022: $125 · 2023: $139 · 2024: $59.28 · 2025: $401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $599.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $598.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celularity INC. | $300.00 | 2019 | |
| Astellas Pharma US INC | $164.16 | 2023-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $84.39 | 2022-2025 | |
| Hologic Sales and Service, LLC | $81.56 | 2021-2025 | Aptima, Thinprep 2000 Processor |
| Exeltis, USA INC. | $78.06 | 2022-2025 | Slynd |
| Abbvie INC. | $65.10 | 2022-2025 | Lo Loestrin Fe |
| Organon LLC | $62.03 | 2022-2025 | Nexplanon |
| Mayne Pharma Commercial LLC | $48.78 | 2024-2025 | |
| Millicent US INC | $31.25 | 2025 | Femlyv, Intrarosa |
| Dexcom, INC. | $29.53 | 2025 | Dexcom G6 Transmitter |
| Coopersurgical, INC. | $29.23 | 2025 | |
| Biogen, INC. | $28.59 | 2025 | Zurzuvae |
| Becton, Dickinson and Company | $24.72 | 2025 | Bd Onclarity |
| Exact Sciences Corporation | $14.79 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.